Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,440 stopped studies mapped to Adenocarcinoma and descendants · 92% state a reason
Over the 1,440 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination… | Phase 1 / Phase 2 | terminated | Apr 5, 2017 | M.D. Anderson Cancer Center | \<75% accrued | Enrollment / accrual |
| NCT06585969 | A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal…(DISCORDANT) | Phase 3 | withdrawn | Sep 19, 2024 | Danish Breast Cancer Cooperative Group | Lack of funding | Funding |
| NCT05928806 | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial(ARCITECT) | Phase 2 | suspended | Jul 3, 2023 | Michael B. Atkins, MD | Interim Analysis | Efficacy / futility |
| NCT06716853 | A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With…(TEM-GU) | Phase 1 / Phase 2 | terminated | Dec 4, 2024 | Genenta Science | Persistent challenges have been encountered in patient recruitment, difficulty in identifying a… | Safety / toxicity |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Feb 15, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05489250 | The PLATON Network(PLATON) | — | terminated | Aug 5, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sponsor Decision | Sponsor / business decision |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High… | N/A | withdrawn | Nov 10, 2025 | City of Hope Medical Center | slow accrual | Enrollment / accrual |
| NCT04258566 | Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies | N/A | terminated | Feb 6, 2020 | National Institutes of Health Clinical Center (CC) | Recruitment difficulty | Enrollment / accrual |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 19, 2024 | Prelude Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant…(Spencer) | Phase 1 / Phase 2 | terminated | Dec 5, 2019 | Enterome | Strategic decision | Sponsor / business decision |
| NCT06290856 | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced… | — | terminated | Mar 4, 2024 | Oslo University Hospital | The platform used for detecting ctDNA was not sensitive enough. | Other (stated, no rule matched) |
| NCT05014698 | IDEntification of New Predisposition Genes in Differentiated THYroid Cancer(IDENTHY-K) | N/A | terminated | Aug 20, 2021 | Nantes University Hospital | end-of-study visit not completed within the protocol timeframe | Other (stated, no rule matched) |
| NCT04095689 | Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple…(INTEGRAL) | Phase 2 | terminated | Sep 19, 2019 | The Methodist Hospital Research Institute | Stopping rules met per protocol, trial will be terminated | Other (stated, no rule matched) |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT04770272 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With…(neoMono) | Phase 2 | terminated | Feb 25, 2021 | Palleos Healthcare GmbH | The trial stopped recruitment prematurely after a first planned interim analysis of the first 100… | Efficacy / futility |
| NCT02917759 | Liver and Biliary Tumor Tissue Registry | — | terminated | Sep 28, 2016 | Mayo Clinic | Lack of funding to support enrollment | Enrollment / accrual |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Phase 1 | terminated | Jan 18, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations… | Phase 2 | terminated | Jun 27, 2024 | Lipomedix Pharmaceuticals Inc. | Sponsor decision | Sponsor / business decision |
| NCT01048853 | Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer | N/A | terminated | Jan 14, 2010 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT04578106 | Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2…(ELPIS) | Phase 2 | terminated | Oct 8, 2020 | Fundacio Clinic Barcelona | The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize… | Enrollment / accrual |
| NCT06408168 | Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone… | Phase 2 | terminated | May 10, 2024 | M.D. Anderson Cancer Center | \<75% Participation | Other (stated, no rule matched) |
| NCT04805788 | Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer | Phase 2 | terminated | Mar 18, 2021 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT05553522 | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2… | Phase 1 | terminated | Sep 23, 2022 | Baptist Health South Florida | Slow enrollment | Enrollment / accrual |
| NCT06649682 | 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC(NYCRRLT) | Phase 1 | suspended | Oct 21, 2024 | Peking Union Medical College Hospital | This trial has been suspended given the concerns of stomach adverse effect in the first dose of… | Safety / toxicity |
| NCT04986852 | Olinvacimab With Pembrolizumab in Patients With mTNBC | Phase 2 | terminated | Aug 3, 2021 | PharmAbcine | Subject recruitment issues and follow-up study plans | Enrollment / accrual |
| NCT07283848 | Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma | Phase 2 | withdrawn | Dec 16, 2025 | Massachusetts General Hospital | The pharmaceutical company is not moving forward with this intervention due to lack of efficacy. | Efficacy / futility |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Phase 1 | terminated | Aug 4, 2023 | Novartis Pharmaceuticals | The decision was not based on any safety concerns | Safety / toxicity |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT03042169 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage…(SURGIGAST) | Phase 3 | terminated | Feb 3, 2017 | University Hospital, Lille | default inclusion | Other (stated, no rule matched) |
| NCT03225547 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast… | Phase 2 | terminated | Jul 21, 2017 | University of Chicago | side effects (rash) | Other (stated, no rule matched) |
| NCT04831138 | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy… | N/A | terminated | Apr 5, 2021 | University of Texas Southwestern Medical Center | The treatment landscape changed and hence unable to recruit patients undergoing only… | Enrollment / accrual |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or… | N/A | withdrawn | Sep 19, 2024 | Duke University | Changing priorities of portfolio | Sponsor / business decision |
| NCT05044676 | Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for…(IMMUNOCELL) | — | terminated | Sep 16, 2021 | Assistance Publique - Hôpitaux de Paris | Abandon of study | Other (stated, no rule matched) |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized… | Phase 2 / Phase 3 | terminated | Dec 28, 2021 | Peking University | Difficult to enroll participants | Enrollment / accrual |
| NCT06347809 | DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in… | — | terminated | Apr 4, 2024 | Mayo Clinic | Closed to consolidate enrollment under another related study | Enrollment / accrual |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian,… | Phase 2 | terminated | Feb 18, 2015 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT06818305 | Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function…(EmFin-Nx) | Phase 2 | terminated | Feb 10, 2025 | Jinling Hospital, China | The patient enrollment rate is proceeding too slowly | Enrollment / accrual |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | Phase 2 | terminated | Mar 21, 2022 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT05583110 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in…(TrasTUCAN) | Phase 2 | terminated | Oct 17, 2022 | Spanish Breast Cancer Research Group | The study was closed early due to safety concerns and an unfavorable benefit-risk balance.… | Safety / toxicity |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER) | Phase 2 / Phase 3 | withdrawn | Jul 25, 2025 | Lantheus Medical Imaging | Operational challenges in patient enrollment | Enrollment / accrual |
| NCT03260504 | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney… | Phase 1 | terminated | Aug 24, 2017 | University of Washington | Insufficient funding | Funding |
| NCT05064111 | Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy | — | suspended | Oct 1, 2021 | University of Arizona | Per PI, the project start is on suspension. | Other (stated, no rule matched) |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | Phase 1 | terminated | Feb 23, 2022 | Blueprint Medicines Corporation | This trial was terminated prior to the initiation of Phase 2 for reasons not due to safety concerns. | Safety / toxicity |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Jan 26, 2021 | Transgene | Sponsor decision following completion of Phase I part not driven by safety reason | Safety / toxicity |
| NCT06320080 | Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of… | Phase 1 | terminated | Mar 20, 2024 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT01946100 | Treatment of Multifocal Lung Adenocarcinoma | N/A | terminated | Sep 19, 2013 | Mayo Clinic | Funding ended prior to completion of enrollment. | Enrollment / accrual |
| NCT05954143 | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Phase 2 | terminated | Jul 20, 2023 | Bolt Biotherapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 12, 2026source: clinicaltrials